Nursel SÜRMELİOĞLU, Yusuf KARATAŞ, Semra PAYDAŞ, Gülşah SEYDAOĞLU

Evaluation of lipid profiles in patients treated with capecitabine

Background/aim: Capecitabine is a prodrug of 5-fluorouracil and has shown significant antitumor activity. The main adverse effects are hand-foot syndrome, diarrhea, and dermatitis. In recent years, hypertriglyceridemia has been reported in patients treated with capecitabine. Dyslipidemia is a rare but important side effect of capecitabine. The aim of this study is to examine the changes in lipid levels during capecitabine treatment and to raise awareness of pharmacovigilance. Materials and methods: In this retrospective study, it was aimed to analyze lipid metabolism after capecitabine treatment and is intended to contribute to the formation of a pharmacoepidemiological database. For this purpose, triglyceride, cholesterol, HDL, LDL, ALT, AST, ALP, MCV, and Hb blood levels of 57 patients treated with capecitabine at the Department of Medical Oncology, Faculty of Medicine, Çukurova University, were examined before and after five cycles of treatment. Results: Blood triglyceride and cholesterol levels were significantly increased after capecitabine treatment. The increase in triglyceride levels was higher than the increase in cholesterol levels. Conclusion: In the light of these findings, monitoring of the lipid profile should be considered in cancer patients treated with capecitabine.

PDF

___

1. Kayaalp OS. Akılcıl Tedavi Yönünden Tıbbi Farmakoloji. 13th ed. Ankara, Turkey: Pelikan; 2012 (in Turkish).
2. Katzung BG, Masters BS, Trevor AJ. Temel ve Klinik Farmakoloji. 12th ed. İstanbul, Turkey: Nobel Tıp; 2014 (in Turkish).
3. Walko CM, Lindley C. Capecitabine: a review. Clinical Therapeutics 2005; 27: 42-44.
4. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001; 40: 85-104.
5. Bozkurt-Duman B, Paydas S, Tetiker T, Gunaldı M, Usul Afsar C, Erçolak V, Haksöyler V, Şimşek-Dilli M. Capecitabineinduced hypertriglyceridemia and hyperglycemia: two cases. Pharmacology 2012; 90: 212-215.
6. Michie CO, Sakala M, Rivans I, Strachan MW, Clive S. The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study. Brit J Cancer 2010; 103: 617-662.
7. Bar-Sela G, Cohensiuis-Kent D, Kornikova O, Haim N. Increase in triglyceride blood level in patients treated with capecitabine: a retrospective survey. Anti-Cancer Drug 2014; 25: 729-734.
8. Seminara P, Losanno T, Emiliani A, Manna G. Cancer chemotherapy and cardiovascular risks: is capecitabineinduced hypertriglyceridemia a rare adverse effect? Cardiology 2010; 116: 42-44.
9. Bar-Sela G, Haim N. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature. Cancer Chemoth Pharm 2009; 63: 779-782.
10. Garg R, Angus E, Fincher S. Capecitabine-induced severe hypertriglyceridaemia and diabetes: a case report and review of the literature. Diabetic Med 2009; 26: 1308-1309.
11. Orphanos GS, Stavrou NG, Picolos MK. Hypertriglyceridemia: an underdiagnosed side effect of capecitabine chemotherapy. Acta Oncol 2010; 49: 262-263.
12. Koutras AK, Habeos IG, Vagenakis AG, Kalofonos HP. Capecitabine-induced hypertrigyceridemia: a report of two cases. Anticancer Res 2006; 26: 2249-2252.
13. Han G, Huang JX. Hypertriglyceridemia and hyperglycemia induced by capecitabine: a report of two cases and review of the literature. J Oncol Pharm Practice 2014; 21: 380-383.
14. Kurt M, Babaoglu MO, Yasar U, Shorbagi A, Guler N. Capecitabine induced severe hypertriglyceridemia: report of two cases. Ann Pharmacother 2006; 40: 328-331.
15. Polinder-Bos HA, Kok EE, Van de Wiel A, Spiering W, Wielders JP, Bloemendal HJ. Severe hypertriglyceridaemia associated with the use of capecitabine. Neth J Med 2012; 70: 104.
16. Javot L, Spaeth D, Scala-Bertola J, Gambier N, Petitpain N, Gillet P. Severe hypertriglyceridaemia during treatment with capecitabine. Brit J Cancer 2011; 104: 1238-1239.
17. Jung HA, Kim HJ, Maeng CH, Park SH, Lee J, Park JO, Park YS, Lim HY, Kang WK. Changes in the mean corpuscular volume after capecitabine treatment are associated with clinical response and survival in patients with advanced gastric cancer. Cancer Res Treat 2015; 47: 72-77.
18. Wenzel C, Mader RM, Steger GG, Pluschnig U, Kornek GV, Scheithauer W, Locker GJ. Capecitabine treatment results in increased mean corpuscular volume of red blood cells in patients with advanced solid malignancies. Anticancer Drug 2003; 14: 119-123.